Robert M. Guthrie, M.D.

 

Home

Short CV

Complete CV

 

Complete CV Table of Contents:

 

Current Position

 

Previous Positions

 

Education

 

Academic Experience

 

Practice Experience

 

Licensure

 

Certifications

 

Hospital Affiliations

 

Professional Organizations

 

National Recognition

 

Honors and Awards

 

Publications

 

Abstracts

 

Presented Papers

 

Book Chapters

 

Editor Reviewed Journal Articles

 

Presentations

 

Approved and Funded Grants/Contracts

 

Grants

 

University Service

 

Hospital Service

 

Community Service

 

CURRICULUM VITAE AND BIOGRAPHICAL SKETCH

 

ROBERT MILLER GUTHRIE, M.D.

 

Office:              The Ohio State University

                        Department of Emergency Medicine

                        1380 Edgehill Road

                        Columbus, OH 43212

                        Phone:  614-298-8052

                        Fax 614-298-8053

                        e-mail;  guthrie.1@osu.edu

 

Personal:          Birthdate:        December 1, 1948

Birthplace:      Huntington, West Virginia

Health:            Excellent

 

 

CURRENT POSITION

            VICE CHAIR FOR DEVELOPMENT, DEPARTMENT OF EMERGENCY MEDICINE,

                        The Ohio State University, July 1, 2004-present

PROFESSOR, DEPARTMENT OF EMERGENCY MEDICINE, The Ohio State University, Columbus, Ohio, 7/1/99-present

 

PROFESSOR, DEPARTMENT OF PHARMACOLOGY, The Ohio State University, College of Medicine, Columbus, Ohio, 7/1/99-present

 

ASSOCIATE DIRECTOR OF CLINICAL PHARMACOLOGY, The Ohio State University, College of Medicine, Columbus, Ohio, 7/1/85-present

Responsibilities:

§         Serve as an experienced, licensed physician supervisor for pharmacological research trials.

§         Review and comment upon the drug protocols from a clinical perspective.

§         Serve as medical consultant for any patient related problems that occur during the drug trials.

 

Major Highlights:

§         Assisted on over 145 projects 

PROFESSOR, DEPARTMENT OF INTERNAL MEDICINE, The Ohio State University, College of Medicine, Columbus, Ohio, 7/1/99-present

 

PREVIOUS POSITIONS

 

ASSOCIATE PROFESSOR OF EMERGENCY MEDICINE, INTERNAL MEDICINE, AND PHARMACOLOGY, The Ohio State University, College of Medicine, Columbus, Ohio, 7/1/92-6/30/99

 

ASSOCIATE PROFESSOR OF FAMILY MEDICINE, INTERNAL MEDICINE, AND PHARMACOLOGY, The Ohio State University, College of Medicine, Columbus, Ohio, 7/1/90-6/30/92

 

ASSISTANT PROFESSOR OF FAMILY MEDICINE AND INTERNAL MEDICINE, The Ohio State University, College of Medicine, Columbus, Ohio, 9/1/82-6/30/90

 

ASSISTANT PROFESSOR OF PHARMACOLOGY, The Ohio State University, College of Medicine, Columbus, Ohio, 7/1/85-6/30/90

 

FACULTY ASSOCIATE, OHIO STATE UNIVERSITY RESEARCH FOUNDATION

7/1/92 - 6/30/94, 50% time.

§         Implemented plans to facilitate industry research contracts

 

DIRECTOR, FAMILY PRACTICE RESIDENCY PROGRAM, Department of Family Medicine, The Ohio State University; April 1983 - June 1990

Responsibilities:

§         Recruit and select residents for the residency program.

§         Direct the educational responsibilities of the Department of Family Medicine toward the residency program, including clinical and didactic programs.

Major Highlights:

§         Experienced dramatic success in recruiting residents with an increase from an anticipated class of nine in 1983-1984 to a nearly full class in 1990.

§         Increased the number of applicants from 10 in 1982 to 45 in 1990 as a result of recruiting efforts.

§         Developed a new, detailed evaluation system for the residents in our department.

§         A review by the ACGME Residency Review Committee found no significant deficiencies in 1988.

§         Implemented new curricular procedures in Geriatrics, Behavioral Science, and Sports Medicine.

§         Filled all six match positions in the 1990 NRMP match.

DIRECTOR, OHIO STATE UNIVERSITY FAMILY PRACTICE CENTER 4/83-7/86

Responsibilities:

Major Highlights:

§         Increased patient visits to the Family Practice Center dramatically, from approximately 650/month in 1982-83 to approximately 1600/month in 1986.

§         Increased our medical student participation from none in 1982-83 to more than 40 in 1985-86.

§         Completed a number of research projects of our own faculty, and developed a clinical research program in the Family Practice Center.

 

DIRECTOR, GENERAL MEDICINE SERVICE at Saint Anthony Medical Center, Columbus, Ohio; November 1, 1985 -  June 30, 1987

Responsibilities:

§         Supervised the two or three OSU Family Medicine residents who are on the General Medicine Service at the Saint Anthony Medical Center, including didactic experiences and direct patient care.

§         Supervised OSU College of Medicine students who rotated on the General Medicine Service.

 

EDUCATION

 

1982                    York Hospital, York, Pennsylvania

                            January 1982 - September 30, 1982

                            Third-Year Family Practice Resident, Full-time

 

1981-1982          York Hospital, York, Pennsylvania

    July 1981 - June 1982

    Part-time, third-year resident, Family Practice

 

1976-1978          Union Memorial Hospital, Baltimore, Maryland

    July 1976 - June 1978

    Internal Medicine Resident

 

1974-1976          University of Maryland Hospital

    Baltimore, Maryland

    June 1974 - June 1976

    Family Practice Resident

 

1970-1974          University of Maryland School of Medicine

    Baltimore, Maryland

    MD., June 1974

    Class President 1972-1974

    Student Council Award 1974

 

1968-1969           University of Glasgow, Glasgow, Scotland

    September 1968 - June 1969  Special student, no degree

 

1966-1970          College of Wooster, Wooster, Ohio

    September 1966 - June 1970

    B.A., June 1970

    Major:  History

 

ACADEMIC EXPERIENCE

 

April 1, 1983-             Director, Family Practice Residency Program 

June 30, 1990             Assistant Professor and Director, Residency Section

                                   Department of Family Medicine, The Ohio State University

 

October 1, 1982-        Associate Director for General Medical

March 30, 1983          Curriculum, Assistant Professor, Residency Section, Department of Family Medicine, The Ohio State University

                                   Major Highlights:

§         Designed and successfully implemented the new General Medical Service at the Saint Anthony Medical Center

 

April 1980-                  Associate Director and Inpatient Supervisor

January 1982                Family Practice Residency, York Hospital, York, Pennsylvania

Major Highlights:

§         Designed, implemented, and supervised a new Family Medicine Inpatient Service

§         Regularly supervised ambulatory care in the Family Practice Center

 

PRACTICE EXPERIENCE

 

January 1982-               Part-time Emergency Physician

September 1982           York Hospital, York, Pennsylvania

 

January 1980-               Emergency Physician

April 1980                    Union Memorial Hospital, Baltimore, Maryland

 

July 1978-                     Private Practice, Drs. Guthrie and Ripley

December 1979            547 6th Avenue, Huntington, West Virginia

 

LICENSURE

 

1982 Ohio #35-04-8192

 

CERTIFICATIONS

            1999- 2009                 Certified as a Clinical Expert in Hypertension by the American

                                                Society of Hypertension

            1983                            American Board of Family Practice, Recertified 2001-2008

1979                                                        American Board of Internal Medicine

            

 

HOSPITAL AFFILIATIONS

 

1982-1992                  Saint Anthony Medical Center, Columbus, Ohio

Medical Education Committee, 1983, 1984

Parenteral Nutrition Committee, 1983

 

1980-1982                   York Hospital, York, Pennsylvania

Ambulatory Care Committee, 1981

Family Practice Audit Committee, 1981

 

1978-1979                  Guthrie Memorial Hospital

Huntington, West Virginia

Associate Administrator

Chairman, Department of Medicine

 

PROFESSIONAL ORGANIZATIONS

 

American College of Physicians

American Academy of Family Physicians

Ohio Academy of Family Physicians

American Society of Hypertension

 

NATIONAL RECOGNITION

 

Jan 2005 – present   Congestive Heart Failure Steering Committee, for Pri-Med Online, the PRI-MED Institute
Jan 2005 – present Editorial Advisory Panel, the Cortland Forum
Dec 2004 – Jan 2005  

STRIVE CME teleconference The Cardiovascular Continuum of Care: Management of ACS form the Hospital to the Office-Based Setting

Sep 2004 –Nov 2004  Everest Expert Exchange national CME teleconference program
July 1, 2003-present    Elected a Fellow of the American College of Physicians (FACP)
July 2003 – present.   

Co-Chair of the Gemifloxacin Primary Care Advisory Panel for Genesoft Pharmaceuticals

July 1984-present  Elected a Fellow of the American Academy of Family Physicians (FAAFP)
2002- present   Co-chair, Vascular Medicine Primary Care Advisory Panel, Bristol-Myers Squibb/  Sanofi.
2002- present   Member, Vascular Medicine Advisory Panel, Bristol-Myers Squibb/ Sanofi.
2001

Member, Expert Panel for “A Consensus Guideline on Lipid

Management for the Primary Physician,” Family Practice Education

Monograph, Illinois Academy of Family Practice.

2001 Chair, “Lipid Links”, a CME Newsletter for Primary Care Physicians published by the Center for Biomedical Communications.
2000- present Editorial Review Board, Journal of Clinical Hypertension.
1999 Editor-in-Chief, “American Herpes Foundation Monitor”, Vol 1, No. 1, American Herpes Foundation.
1999-present Chair, Plavix Pregnancy Care Advisory Panel, Bristol-Myers Squibb/Sanofi
1999-present Member, Cholesterol National Education Initiative, Parexel/Astra-Zeneca
1999-present  Chair, Moxifloxican Ambulatory Care Advisory Panel, Bayer Pharmaceuticals
Sept-Nov 1998 American Academy of Family Physicians Home Study Audio Speaker: “Hypertension Management” and “Cholesterol Management”
Sep 13, 1997 Co-Chair of National Video Conference: Management of Coronary Artery Disease: New Dimensions. This was a National CME Conference with physician participants. I was the Co-Chair and was significantly involved in the development and implementation. The program was CME approved through The Ohio State University.
1997-1998 Chair, Avapro Primary Care Advisory Panel, Bristol-Myers Squibb
1998-present Medical Advisor-First MI Risk Reduction Program-Bristol Myers Squibb. This program will enroll more than 10,000 patients in a database to evaluate their risk for a first MI and will evaluate the effect on medication compliance with a special education program.
1996-Present Invited to serve on Bronchitis Advisory Panel, Bayer Pharmaceuticals
1997-Present Invited to serve on Sinusitis Advisory Panel, Bayer Pharmaceuticals
1996 Invited to serve on the Cardiovascular Advisory Panel, Bristol-Myers Squibb
1990-1994 Invited to serve on ACE Inhibitor Advisory Panel for Bristol Myers-Squibb, Inc
1985-1990 Invited by the United States Pharmacopeial to serve on the Family Practice Advisory Panel
1986-1998 Appointed to serve on the Diagnostic and Therapeutic Technology Assessment (DATTA) panel of the American Medical Association
1987-1994  Editorial Review Panel, Postgraduate Medicine
1990-2000 Elected by the 1990 and 1995 United States Pharmacopeial Conventions to the USP Committee of Revision as Chairman of the Family Practice Advisory Panel. The USP is the oldest professional organization in the United States. It is empowered by Congress to set standards for drug purity, quality, and labeling. It also publishes comprehensive drug information in the USPDI. The Committee of Revision is composed of 118 individuals drawn from medicine, pharmacy, pharmaceutical manufacturing, and government and private organizations. I am the only Family Physician on the Committee for this five-year period and I will chair the Family Practice Sub-Committee.
1994-2000 Invited to be one of only 55 participants at the USP 2020 Conference, planning the future of the USP to the year 2020.
1990-1998 Editorial Review Panel, Journal of Family Practice.
1993-Present Grant Reviewer, American Academy of Family Physicians Foundation.
1995-1997 Chair, Family Practice Advisory Panel, Bristol-Myers Squibb Anti-Infective Division.
1998-Present Reviewer, Chest
1998-Present Editorial Review Panel, Journal of Clinical Hypertension

 

HONORS AND AWARDS

 

June 1998 – Josephine Failer award.  Presented by the “Friends of WOSU”.  I was awarded this award, which is given annually in recognition of outstanding volunteer service to the WOSU Stations.

Ohio Academy of Family Physicians Research Award at OAFP Research Day, March, 1988

Listed in Men of Achievement, Cambridge, England, 1987

Fellow, American Academy of Family Physicians, 1984

Who's Who in American Colleges and Universities, 1974

University of Maryland School of Medicine

§        Class President, 1972-1974

§        Student Council Award, 1974

College of Wooster

§         Departmental Honors, Department of History, 1970

 

 

PUBLICATIONS

 

Guthrie R:  Meeting Lipid-Lowering Guidelines with Statin Treatment (Part II):  Rosuvastatin and Atorvastatin.  Cardiovascular Reviews and Reports, 2004;  25:  11-17.

 

Guthrie R.Meeting Lipid-Lowering Guidelines with Statin Treatment (Part I):  Analysis and Implementation of Guidelines.  Cardiovascular Reviews and Reports, 2003;  24:  573-576..

 

Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, and Cressman MD.  Beneficial effects of rosuvastatin alone  and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.  Amer J Cardiology, 2003;  91:  1304-1310.

 

Guthrie RM, Graff A, Mroczek WJ, ElHati SE, and Reeves RA:  Double Blind Withdrawal of Omapatrilat After Stable Long Term Administration Demonstrates Persistence of Antihypertensive Efficacy.  Journal of Clinical Hypertension, 2002;  IV:  169-172

 

Guthrie RM:  Safety and Efficacy of Fluoroquinolones in the4 Elderly, 2001;  9:  44-52

           

Guthrie RM:  Community-Acquired Lower Respiratory Tract Infections:  Etiology and Treatment. Chest, 2001;  120:  2021-2034.

 

Guthrie RM:  Compliance with Pravastatin is Associated with other Risk Modification but is not Enhanced by Postal and Telephone Reminders:  Results of the First Myocardial Infarction Risk Reduction Program.  Clinical Therapeutics, 2001;  120:  970-980.

.

Wewers ME, Ahijevych KL, Dhatt RK, Guthrie RM, et al. Cotinine Levels I, Southeast Asian Smokers. Nicotine and Tobacco Research, 2000; 2:85-91.

 

Raskin P, Guthrie R, Flack JM, Reeves and Sani R: The Long-term Antihypertensive Activity and Tolerability of Irbesartan with Hydrochlorothiazide. Journal of Human Hypertension, 1999;13,683-687.

 

Messerli F, Frishman W, Elliott W for the Trandolopril Study Group: Effects of Verapamil and Trandolapril in the Treatment of Hypertension. Am J Hypertension, 1998;11:322-327.

 

Guthrie RM:            Management of Elevated Cholesterol in the Elderly. Clinical Geriatrics, 1998; 6:35-47

 

Guthrie RM:  A Multicenter, Community-based Study of Doxazosin in Patients with Concomitant Mild-to-Moderate Hypertension and Symptomatic Benign Prostatic

Hyperplasia:  The Hypertension and BPH Intervention Trial (HABIT).   Clinical Therapeutics, 1999;21,1732-1748.

 

Kochar W. Fablocki CJ, Guthrie R, et al:  Matrix Study of Irbesartan with Hydrochlorothiazide in Mild-to-Moderate Hypertension.  American J Hypertension.  1999;12:797-805.

 

Oparil S. Guthrie R, Lewin A, et al:  An Elective Titration Study of the Comparative Effectiveness of Two Angiotensin II Receptor Blockers, Irbesartan and Losartan.  Clinical Therapeutics, 1998; 20:398-409

 

Pool JL, Guthrie RM, Littlejohn TW, III, Raskin P, Shepherd A, Weber MA, et al:  Dose-related Anti-hypertensive Effects of Irbesartan in Patients with Mild-to-Moderate Hypertension.  Am J Hypertension.  1998; 11:462-470.

 

Guthrie RM, Saini R, Herman T, Pleskow W, Sprecher D and Collins G: Efficacy and Safety of Irbesartan, The Angiotensin II Receptor Antagonist.  Clinical Drug Investigations, 1998; 217-227.    

 

Guthrie RM:  Doxazosin for Benign Prostatic Hyperplasia in Primary Care.  Clinical Therapeutics, 1997; 19:1269-1277.

 

Guthrie RM:  Treatment of Benign Prostatic Hyperplasia in Elderly Patient:  What are the Special Issues.  Postgraduate Medicine, 1997; 101:141-160.

 

Moeschberger M, Anderson J, Kuo Y, Chen M, Wewers M, and Guthrie R:  Multivariate Profile of Smoking in Southeast Asian Men:  A Biochemically Verified Analysis – Multivariate Smoking Profile.  Preventive Medicine, 1996; 26:53-58.

 

Fawzy A, Fonterot C, Guthrie R, Bandier M:  Practice Patterns Among Primary Care Physicians in Benign Prostatic Hyperplasia and Prostate Cancer.  Family Medicine 1997; 29:321-325.

 

Guthrie RM:  Treatment of Non-Insulin Dependent Diabetes Mellitus with Metformin.  The Journal of the American Board of Family Practice, 1997; 10:213-221.

 

Guthrie R, Lott J, Cattaneo S, Guthrie B, and Witmer V:  Proteinuria as a Marker for Patients at Increased Risk for Target Organ Damage form Hypertension.  J Fam Practr, 1996: 42, 85.

 

Wewers M, Dhatt R, Moeschberger M, Guthrie R, Kuhn P, and Chen M:  Misclassification of Smoking Status Among Southeast Asian Adult Immigrant.  American Journal of Respiratory and Critical Care Medicine, 1995; 152, 1917-1921.

 

Guthrie R, Reggi D, Plesher M, Saini R, Battikhe J, and Ju H:  A Comparison of the Combination of Fosinopril and Hydrochlorothiazide with Placebo in Patients with Mild-to-Moderate Hypertension Utilizing 24-hour Ambulatory Monitoring.  American Journal of Hypertension, 1996; 9:306-311.

 

Tice F, Peterson J, Orsinelli D, Binkley P, Cody R, Guthrie R, and Pearson A:  Vascular Hypertrophy is an early finding in Essential Hypertension and is Related to Arterior Pressure Waveform Contour.  American Heart Journal, 1996; 132:621-627.

 

Guthrie R:  Terazosin in the Treatment of Benign Prostatic Hyperplasia: A Primary Care Trial, J Fam Pract., 1994; 39, 129-133.

 

Chen M, Guthrie R, Moeschberger M, et al. Lessons Learned and Baseline Data From Initiating Smoking Cessation Research With Southeast Asian Adults. Asian American and Pacific Islands Journal of Health, 1993; 1, 194-214.

 

Chen M, Anderson J, Moeschberger M., Guthrie R, Kuhn P, and Zaharlick A:  An Evaluation of Heart Health Education for Southeast Asians, American Journal of Preventive Medicine, 1994; 2(4):303-308.

 

Guthrie R, and Lott J:  Increased Proteinuria in African Americans with Hypertension and Diabetes; Journal of Family Practice, 1993; 37:253-256.

 

Chen M, Zaharlick A, Kuhn M, and Guthrie R: Implementation of the Indigenous Model for Health Education Programs Among Asian Minority Patients; Journal of Health Education, 1992; 23, 400-403.

 

Anderson J, Moeschberger W, Chen M, Kuhn P, Wewers M, and Guthrie R:  An Acculuration Scale for South East Asian Immigrants; Social Psychiatric Epidemiology; 1993; 28:134-141.

 

Chen M, Kuhn M, Guthrie R, Li W, and Zoharlick A:  Promoting Heart Health for Southeast Asians:  A Database for Planning Interventions.  Public Health Reports, 1991; 106, 304-309.

 

Contos DA, Nowouts, Guthrie R, Mays D, and Gerber N:  Non-Linear Elimination of Methyprylon (Noludar) in an Overdose Patient:  Correlation of Clinical Effects with Plasma Concentration.  J Pharmaceutical Sciences, 1991; 80, 768-771.    

 

Guthrie R:  Streptococcal Pharyngitis:  Am Fam Physician, 1990; 42, 1558-1560.

 

Gerber N, Mays D, Donn K, Laddu A, Guthrie R, Turlapaty P, Quon C, and Rivenburg W:  Safety, Tolerance and Pharmacokinetics of Intravenous Doses of the Phosphate Ester of 3-Hydroxymethyl-5, 5-Diphenylhydantoin: A New Prodrug of Phenytoin.  J Clin Pharmacol 1988; 28:1023-1032.

 

Guthrie R:  Erythromycin in Acute Pharyngitis:  A Comparison of Efficacy and Patient Tolerance of Two Twice-Daily Preparations.  Clin Therap 1988; 10:530-535.

 

Guthrie R, Bakenhaster K, Nelson R, and Woskobnick R:  Branhamella Catarrhalis Sepsis:  A Case Report and Review of the Literature.  J Infect Dis 1988; 158:907-908.

 

Martin R and Guthrie R:  Office Evaluation of Dementia.  Postgrad Med 1988; 84:176-187.

 

Ricer R and Guthrie R:  Allergic Vaginitis:  A Case Report of A Possible New Syndrome.  J Reprod Med 1988; 33:781-783.

 

Guthrie R, Sickles R, Draeger S, et al:  The Incidence of Legionella Pneumophilia as The Cause of Acute Ambulatory Lower Respiratory Tract Infection.  J Fam Pract 1988; 26:633-635.

 

Guthrie R:  Resident Recruiting by Direct Mail.  Family Medicine 1988; 20:173-174.

 

Guthrie R, Ruoff G, Rofman B, Karp R, Brown S, and Schulz G:  The Aetiology of Acute Pharyngitis and Clinical Response to Empirical Therapy with Erythromycin Versus Amoxicillin.  Family Practice 1988; 5:29-35.

 

Guthrie R, Lott J, Kriesel S, and Miller I:  Does The SG Dipstick Meet Medical Needs For Urine Specific Gravity.  J Fam Pract 1987; 25:512-514.

 

Guthrie R and Martin R:  EKG Stress Testing.  Patient Care 1987; 21:146-149.

 

Guthrie R and Lott J:  Abnormal CK-MB Following an Amitriptyline Overdose:  A Case Report and Review of the Literature.  J Fam Pract 1986; 22:550-555.

 

VandeCreek L, Moore T, Davis R, Rosen R, and Guthrie R:  The Effects of Glucagon and Metoclopromide as Measured by the Electrogastrogram.  Amer J Gastro 1986; 81:955-959.

 

Guthrie R, Monk J, and Zerbe D:  The Determination of Urine Specific Gravity.  Fam Pract Res 1983; 3:84-92.

 

Guthrie R and Monk J:  Osteomyelitis of the Symphysis Pubis:  A Complication of Cardiac Catheterization.  Br J Clin Pract 1989; 43:383-385.

 

Revak D, Swan R, Guthrie R, and Lubbers J:  Brucellosis:  Beware of Unpasteurized Dairy Products When Traveling to Brucella-endemic Foreign Countries.  Postgrad Med, May 1, 1989; 85(6):101-104.

 

 

ABSTRACTS

 

Guthrie RM: Doxazosin as Add-On Therapy for Poorly Controlled Hypertension: Hypertension and Benign Prostatic Hyperplasia Intervention Trial (HABIT). J Hypertension, 2001;14 (No. 4, Part 2):105A.

 

Guthrie RM: Doxazosin as Add-On Therapy for Poorly Controlled Hypertension: Hypertension and Benign Prostatic Hyperplasia Intervention Trial (HABIT). J Hypertension, 2001;19(Suppl 2):S146-7.

 

Guthrie RM, Graff A, Mroczek WJ, ElHati SE, and Reeves RA.  Long Term Stable Administration of Omapatrilat Demonstrates persistence of Antihypertension Efficacy. J Hypertension, 2000;18(Suppl 2):S84.

 

Guthrie RM, Graff A, Mroczek WJ, ElHati SE, Double-Blind Withdrawal of Omapatrilat After Long-Term Stable Administration Demonstrates Persistence of Antihypertensive Efficacy.  Am J Hypertension 2000; 13(Vol 4, Part 2):135A.

 

Ruddy M, Guthrie R, Pupademetriou, v, Moulton K and Saini R:  The Safety and 24-hour Antihypertensive Efficacy of the Vasopeptide Inhibitor Omapatrilat:  A Pilot Study.  Am J Hypertension, 1999;125A.

 

Guthrie R, Weber M, and Plat P:  Dose-Response of the Combination of Irbesartan and Hydrochlorothiazide in Hypertensive Patients.  Am J Hypertension, 1999; 123A

 

Guthrie R, Flack J, Zusman R, et al:  Long Term Therapy with Irbesartan and Hydrochlorothiazide.  Am J Hypertension, 1998; 45A.

 

Guthrie RM and Siegel RL:  Effect of Doxazosin Therapy on Symptoms of Benign Prostatic Hyperplasia and Sexual Function in Hypertensive Men.  Br J Urology, 1997, 80(Suppl 2), 217.

 

Guthrie RM:  Doxazosin in Concomitant Hypertension and Symptomatic Benign Prostatic Hyperplasia:  A Multicenter Study.  Am J Hypertension, 1997; 10(Part 2), 82A.

 

Guthrie RM:  Doxazosin for Treatment of Benign Prostatic Hyperplasia in Normotensive and Hypertensive Patients.  Am J Hypertension, 1997; 10(2), 83A.

 

Kochar W, Fablocki CJ, Guthrie R, et al:  Irbesartan in Combination with Hydrochlorothiazide in Mild-to-Moderate Hypertension.  Am J Hypertension, 1997; 10(2), 106A.

 

Guthrie RM, Saini R, Harrah S, et al:  Dose-Related Reductions in Blood Pressure with Irbesartan, The Angiotensin II Receptor Antagonist.  Am J Hypertension, 1997; 10(2), 172A.

 

Guthrie RM:  Doxazosin in Concomitant Hypertension and Symptomatic Benign Prostatic Hyperplasia:  A Multicenter Study.  J Gen Int Med, 1997; 12(Suppl 1), 120.

Guthrie RM:  Doxazosin for Treatment of Benign Prostatic Hyperplasia in Normotensive and Hypertensive Patients.  J Gen Int Med, 1997; 12(Suppl 1), 120.

 

Fawzy A, Fonerot C, Baudier M, Guthrie R, and Siegel R:  Current Practice Patterns Among Primary Care Physicians in Management of Benign Prostatic Hyperplasia and Prostate Cancer Screening.  JAOA 1996; 96:490, pg. 013.

 

Guthrie RM:  Doxazosin for Treatment of Benign Prostatic Hyperplasia (BPH) and Concomitant Hypertension:  Results of a 6-month Follow-up Patient Survey.  JAOA 1996; 96:536, pg. 21.

 

Guthrie RM:  Doxazosin for the Treatment of Patients with Hypertension and Symptoms of Benign Prostatic Hyperplasia (BPH).  JAOA 1996; 96:536, pg. 22.

 

Fonterot C, Fawzy A, Baudier M, Guthrie R, Siegel R:  Current Practice Patterns Among Primary Care Physicians in Management of BPH and Prostate Cancer Screening.  J Urol 1996; 155(Suppl ):708A (#1587).

 

Guthrie RM:  Doxazosin for the Treatment of Patients with Hypertension and Symptoms of Benign Prostatic Hyperplasia.  Am J Hypertension 1996; 9(2):119A.

 

Guthrie RM:  Doxazosin is Effective Add-on Anti-hypertensive therapy in Concomitant Benign Prostatic hyperplasia (BPH) and Refractory Hypertension (HTN).  J Gen Int Med, 1998: 13 (Suppl), 13.

 

Pool JL, Guthrie RM, Littlejohn T, Raskin P, Shepherd A, Weber M, Weir M, Wilson T, Wright J, deRuyter H and Reeves R:  The Anti-hypertensive Effects of Irbesartan in Patients with Mild-to-Moderate Hypertension.  Am J Hypertension 1996; 9(2):152A.

 

Wewers ME, Kuhn P, Moeschberger M, Guthrie R, and Chen MS:  Effectiveness of Lay-led Smoking Cessation intervention Among Southeast Asian Immigrants.  Amer J Respiratory and Critical Care Medicine 1996; 153(4):A31. 

 

Guthrie R, Lott J, Guthrie B, Cattaneo S, and Witmer V:  Proteinuria as a Marker for Patients at Increased Risk for Target Organ Damage from Hypertension and Diabetes Mellitus.  Am J Hypertension, 1995; 87A.

 

Guthrie R, Reggi D, Plesher M, Saini R. Battikha J, and Ju H:  A Comparison of the Combination of Fosinopril and Hydrochlorothiazide with Placebo in Patients with Mild-to-Moderate Hypertension Utilizing 24-hour Ambulatory Monitoring.  American Journal of Hypertension, 1994, 7, 39A.

 

Guthrie, R: The Treatment of Concomitant Hypertension and Prostatic Obstructive Symptoms with Terazosin. American Journal of Hypertension, 1993; 6, 1358

 

Contos D, Mays D, Guthrie R, and Gerber N:  Reverse Phase High Performance Liquid Chromatography (HPLC) Assay of Methyprylon (Noludar) and its Major Dehydro Metabolite 5-Methylpyrithyldione (Met II) in Plasma of an Overdosed Patient.  Fed Proc (abstract) 1986; 45:205.

 

PRESENTED PAPERS

 

Guthrie RM.  Doxazosin Add-On Therapy for Poorly Controlled Hypertension: Hypertension and Benign Prostatic Hyperplasia Intervention Trial (HABIT). European Society of Hypertension Eleventh Meeting, Milan, Italy, June 17, 2001.

 

Guthrie RM.  Doxazosin Add-On Therapy for Poorly Controlled Hypertension: Hypertension and Benign Prostatic Hyperplasia Intervention Trial. American Society of Hypertension Sixteenth Scientific Meeting, San Francisco, CA, May 18, 2001.

 

Guthrie RM, Graff A, Mroczek WJ, ElHati SE, Reeves RA:  Long-Term Stable Administration of Omapatrilat Demonstrates Persistence of Antihypertensive Efficacy.  European Society of Hypertension Tenth Meeting, Gutenburg, Sweden, June 1, 2000.

 

Guthrie RM, Graff A, Mroczek WJ, ElHati SE, Reeves RA:  Double-Blind Withdrawal of Omapatrilat After Long-Term Stable Administration Demonstrates Persistence of Antihypertensive Efficacy.  American Society of Hypertension Fifteenth Scientific Meeting, New York, NY, May 19, 2000.

 

Guthrie RM.  Symposium Chair and Presenter:  Issues in the Management of Lower Respiratory Tract Infections.  American Academy of Family Physicians Annual Meeting, Satellite Symposium, February 20, 2000, Dallas, TX.

 

Ruddy M, Guthrie R, Papademetriou V. Moulton K, and Saini R:  The Safety and 24-hour Antihypertensive Efficacy of the Vasopeptidase Inhibitor Omapatrilat:  A Pilot Study.  American Society of Hypertension, New York City, May 21, 1999

 

Panel Member, First International Moxifloxacin Symposium, Feb 20, 1999, Berlin, Germany.

 

Guthrie R:  Dose Response of the Combination of Irbesartan and Hydrochlorothiazide in Hypertensive Patients.  American society of Hypertension.  New York City, May 21, 1999.

 

Guthrie R, Flack J, Zusman R, et al:  Long Term Therapy with Irbesartan and Hydrocholorothiazide.  American Society of Hypertension, New York City, Nov, 1998

 

Guthrie RM, Saini R, Harrah S, et al:  Dose Related Reductions in Blood Pressure with Irbesartan, The Angiotensin II Receptor Antagonist.  International Symposium on Angiotensin II Antagonist,  London, United Kingdom, September 29-30, 1997.

 

Guthrie RM, Ricer R, Kuritzky L:  Syndrome X.  American Academy of Family Physicians Scientific Assembly, Chicago, Illinois, September 20, 1997.  Symposium Chairman, and presented on Cholesterol Disorders.

Guthrie RM, Ham RJ, Jeste D, and Fraser M:  Evaluation and Managing Dementia in the Elderly Patient.  American Academy of Family Physicians Scientific Assembly, Chicago, Illinois, September 19, 1997.  Symposium Chairman.

 

Guthrie RM, Ricer R, and Kuritzky L:  Issues in the Aging Male.  American Academy of Family Physicians Scientific Assembly, Chicago, Illinois, September 18, 1997.  Symposium Chairman, and presented on Benign Prostatic Hyperplasia.

 

Guthrie RM and Siegel RL:  Effect of Doxazosin in Therapy on Symptoms of Benign Prostatic Hyperplasia and Sexual Function in Hypertensive Men.  Societiete Internationale d'Urologie 14th World Congress, Montreal, Quebec Canada, September 9, 1997.

 

Guthrie RM:  Doxazosin in Concomitant Hypertension and Symptomatic Benign Prostatic Hyperplasia:  A Multicenter Study.  American Society of Hypertension, San Francisco, California, May 29-31, 1997.

 

Guthrie RM:  Doxazosin for Treatment of Benign Prostatic Hyperplasia in Normotensive and Hypertensive  Patients.  American Society of Hypertension, San Francisco, California, May 29-31, 1997.

 

Kochar M, Zablocki CJ, Guthrie R, et al:  Irbesartan in Combination with Hydrochlorothiazide in Mild-to-Moderate Hypertension.  American Society of Hypertension, San Francisco, California, May 29-31, 1997.

 

Guthrie RM, Saini R, Harrah S, et al:  Dose Related Reductions in Blood Pressure with Irbesartan, The Angiotensin II Receptor Antagonist.  American Society of Hypertension, San Francisco, California, May 29-31, 1997.

 

Guthrie RM:  Doxazosin in Concomitant Hypertension and Symptomatic Benign Prostatic Hyperplasia:  A Multicenter Study.  American Society of General Internal Medicine, Washington, D.C., May 3, 1997.

 

Guthrie RM:  Doxazosin for Treatment of Benign Prostatic Hyperplasia in Normotensive and Hypertensive Patients.  Society of General Internal Medicine, Washington, D.C., May 3, 1997.

 

Guthrie RM:  Infections in the Elderly.  American College of Osteopathic Family Physicians Annual Meeting, Anaheim, California, March 12, 1997.

 

Guthrie RM:  Doxazosin for the Treatment of Patients with Hypertension and Symptoms of Benign Prostatic Hyperplasia.  American Osteopathic Association, Las Vegas, Nevada, October 9, 1996.

 

Guthrie RM:  Doxazosin for the Treatment of Patients with Hypertension and Symptoms of Benign Prostatic Hyperplasia:  Results of a 6-month Follow-up Patient Survey.  American Osteopathic Association, Las Vegas, Nevada, October 9, 1996.

 

Guthrie RM:  Syndrome X:  The Treatment of Hypertension in Syndrome X. American Academy of Family Physicians, New Orleans, LA, October 3, 1996.

 

Guthrie RM:  Doxazosin for the Treatment of Patients with Hypertension and Symptoms of Benign Prostatic Hyperplasia.  American Society of Hypertension, New York, New York, May 17, 1996.

 

Chen M, Guthrie R, Moeschberger M, Wewers M:  Lay led Smoking Cessation approach for Southeast Asian Men:  Intervention Data.  Annual Meeting of the American Public Health Association, New York, New York, November 20, 1996.

 

Pool JL, Guthrie RM, Littlejohn T, Raskin P, Shepherd A, Weber M, Weir M, Wilson T, Wright J, DeRuyter H, and Reeves R:  The Anti-hypertensive Effects of Irbesartan in Patients with Mild-to-Moderate Hypertension.  American Society of Hypertension, New York, New York, May 17, 1996.

 

Guthrie RM:  The Treatment of Hypertension in Syndrome X.  American Academy of Family Physicians Annual Meeting, New Orleans, Louisiana, October 3, 1996.

 

Wewers MR, Kuhn P, Moeschberger M, Guthrie R, and Chen MS:  Effectiveness of lay-led Smoking Cessation Intervention among Southeast Asian Immigrants. 1996 International Conference of Lung Health, American Thoracic Society/American Lung Association, New Orleans, Louisiana, May 1996.

 

Guthrie R, Lott J, Guthrie B, Cattaneo S, and Witmer V:  Proteinuria as a Marker for Patients at Increased Risk for Target Organ Damage from Hypertension and Diabetes Mellitus American Society of Hypertension, New York, New York, May 18, 1995.

 

Pearson A, Peterson J, Binkley P, Cody R, and Guthrie R:  A Carotid Thickening Precedes Ventricular Remodeling in Early Essential Hypertension and is Significantly Related to Early Wave Reflection.  American College of Cardiology, March 20, 1995.

 

Chen M, Guthrie R. Moeschberger M, Kuhn P and Anderson J:  Data From the Lay-led Smoking Cessation Approach to South-East Asian Men.  American Public Health Association, Washington, D.C., 11/2/94.

 

Efficacy and Safety of Fosinopril/Hydrochlorothiazide Combinations on Ambulatory Blood Pressure Profiles in Hypertension, American Society of Hypertension; New York, New York, May 12, 1994.

 

The treatment of Concomitant Hypertension and Prostatic Obstructive Symptoms with Terazosin; American Society of Hypertension; New York, New York, May 20, 1993.

 

Renal Issues in Hypertension, American Academy of Family Physicians Annual Meeting, Washington, D.C., September 27, 1991.

 

Treatment of Lipid Disorders, American Academy of Family Physicians Annual Meeting, Washington, D.C., September 26, 1991.

 

Vitamin Disintegration in Simulated Gastric Fluid, North American Primary Care Research Group Annual Meeting, Richmond, Virginia, April 14, 1992.

 

Allergic Vaginitis:  A Report of a Possible New Syndrome, North American Primary Care Research Group Annual Meeting, San Antonio, Texas, April 14, 1989.

 

Common Problems With Case Report Forms, Associates of Clinical Pharmacology Annual Meeting, New Orleans, April 12, 1989.

 

The Incidence of Legionella Pneumophilia as the Cause of Acute Ambulatory Lower Respiratory Tract Infections, Ohio Academy of Family Physicians Annual Meeting, Toledo, Ohio, August 6, 1988.

 

The Incidence of Legionella Pneumophilia as the Cause of Acute Ambulatory Lower Respiratory Tract Infections, Ohio Academy of Family Physicians Research Day, Columbus, Ohio, March 12, 1988.

 

Erythromycin in Acute Pharyngitis, The University of Western Ontario Research Day, London, Ontario, Canada, September 25, 1987.

 

Direct Mail Resident Recruiting - A Three Year Experience, the Society of Teachers of Family Medicine Annual Meeting, April 28, 1987.

 

The Etiology of Acute Pharyngitis and Its Response to Empiric Therapy to PCE and Amoxicillin, the University of Western Ontario Research Day, October 3, 1986.

 

Direct Mail Resident Recruiting:  Factors Influencing the Candidates' Response and Selection Patterns, Northeast Regional Meeting, Society of Teachers of Family Medicine, Dayton, Ohio, October 24, 1984.

 

The Determination of Urine Specific Gravity North American Primary Care Research Group, Ninth Annual Meeting, Banff, Alberta, Canada, April 19, 1983.

 

BOOK CHAPTERS

 

"Benign Prostatic Hyperplasia", The Manual of Family Practice, Ed., Robert Taylor, M.D., Little, Brown & Company, pp. 408-411, 1997.

 

“Benign Prostatic Hyperplasia”, The Manual of Family Practice, Ed., Robert Taylor, M.D., Little, Brown & Company, 2nd edition, in press.

 

EDITOR REVIEWED JOURNAL ARTICLES

 

Guthrie RM.  CAP and AECB: The Need for a Regimen That the       Bugs Can’t Resist:             Consultant, 2004:  44 (7):  S50-S52

 

Gotto AM, Guthrie RM, and Ito, MK.  Guide to Dyslipidemia.  Cardiology Special Edition, February 2004

 

Guthrie KE and Guthrie R.  Patient Education for Cholesterol      Management:  Practical Lipid Management,  April 2004, 9-10.   

 

Guthrie RM.  Proactively Identifying Patients at Risk for CHD:  Johns Hopkins Advanced Studies in Medicine, 2004;  4 (1B):  S62.

 

Guthrie RM.  An Aggressive and Safe Approach for Dyslipidemia Drug Therapy.  Johns Hopkins Advanced Studies in Medicine, 2004;  4 (1B):  S44-S52.

 

Guthrie R.  Book Review of  Clinical Management of Hypertension, 6th Edition, by Marvin Moser MD.  Journal of Clinical Hypertension, 2004;  6:  50.

 

Guthrie R.  Counseling Patients About Lipid Management.  Part I.  What are the Goals

Of Therapy?   Practical Lipid Management. 2003, Medical World Business Press.

 

Weiss K, Tillotson GS, and Guthrie R.  Fluoroquinolones for

Respiratory Infection:  Too Valuable to Overuse (and Too Valuable to Misuse!).  Chest, 2002;  122:  1102-1103.

 

            Book Review of the Atlas of Heart diseases – Hypertension:  Mechanisms and Therapy

            Ed. By Norman K. Hollenberg.  Journal of Clinical Hypertension, in press.  

 

Guthrie RM, Jacobs M, Low D, Salma T, and Mandel L.  Treating Respiratory Infections in the Face of Resistance:  The Role of the New Quinolones in Primary Care.  CD Rom program from a Satellite Symposium at the AAFP 2000.

 

Bruntos s, Chilton R, Guthrie RM, Iltz J, and Ruoff G.  A Consensus Guideline on Lipid Management for the Primary Care Physician.  Monograph under preparation through the Illinois Academy of Family Physicians.

 

Dodick DW, Gallagher RM, and Guthrie RM.  Optimizing Migraine Therapy:  A Patient Centered Approach.  March 2001.  A CME Audio Home Study program through Parexel Inc.

 

Guthrie RM. Emerging Issues in the Management of Hypertension: Diseases of the Prostate. Post-Graduate Medicine Special Report, September 1999, 31-39.

 

Guthrie RM.  Issues in the Management of Lower Respiratory Tract Infections. Meeting Reporter Supplement to Journal of Gender-Specific Medicines, April 2000.

 

Guthrie, RM, Managing Lower RTI’s in Outpatients: The Primary Care Perspective. J Respiratory Diseases, 1999;20 (Oct Suppl 10A), S19-S26. Co-Chair of Symposium.

 

Guthrie R, Kaplan NM, and Lepor H, Management of the Patient with Hypertension and Benign Prostatic Hyperplasia: A Round Table Discussion.  Monograph produced by Albert Einstein College of Medicine and Montifiore Medical Center, Bronx, New York, September 1999.

 

Guthrie R:  Fluoroquinolones in Family Practice.  Infectious Diseases in Clinical Practice, 1998; 7 (Suppl 3):S203-S205.

 

Guthrie R:  The Role of Quinolones in the Treatment of Acute Rhinosinusitis:  Introduction.  Infections in Medicine, 1998, 15 (Suppl): S5.

 

Guthrie R: and Martin R:  EKG Stress Testing.  Patient Care 1987; 21:146-149.

§         Developed concept for article.  Collected resources.  Wrote and revised manuscript.  60%.

 

Ward T and the Fosinopril Investigators:  The Addictive Effect of Fosinopril in Patients Taking Chlorthalidone for the Treatment of Mild-to-Moderate Essential Hypertension.  Drug Investigators 3(Suppl 4): 25-31, 1991.

§         Participated in collection of patient data.  10%.

 

Guthrie R:  Fosinopril, an overview.  Am J Cardiol 1993; 72 (Suppl):22H-24H.

 

PRESENTATIONS

 

For the last 15 years I have regularly delivered about 30 CME presentations per year around the country.  Topics include:  The Management of Hypertension, Treatment of Lipid Disorders and Alpha Blockers to Treat Symptomatic BPH.  Audiences include University Medical Centers (Johns Hopkins, West Virginia University, Marshall University), major Teaching Hospitals (Shadyside in Pittsburgh, Rancho Los Amigos in Los Angeles, Humana in Louisville), and state and county Medical and Specialty Societies. 

 

APPROVED AND FUNDED GRANTS/CONTRACTS

 

"Lay-Led Smoking Cessation Approach for Southeast Asian Men."  National Heart, Lung, and Blood Institute, NIH.  $1,450,000.00.  Co-Author and Co-Principal Investigator. 9/1/90-8/1/95.

 

"Accessible Screening and International and Neighborhood Services (ASIANS) Office of Minority Health and Human Services, U.S. Department of Health and Human Services.  $150,000.  Co-Author and Co-Principal Investigator. 7/1/95 - 6/30/97.

 

"Southeast Asian Women:  Their Smoking and Passive Smoking."  National Heart, Lung and Blood Institute, NIH.  $49,944.00.  Co-Investigator. 6/1/93 - 6/30.94.

 

"Southeast Asian Smokers' Study."  National Heart, Lung, and Blood Institute, NIH. $68,986.00.  Co-Investigator. 3/15/92 - 8/30/92.

 

"Heart Health for Southeast Asians."  Office of Minority Health,  U.S. Department of Health and Human Services.  $199,967.00  Co-Author and Co-Principle Investigator. 11/1/88 - 2/28/91.

 

A phase 3, Randomized, Three-Arm, Double-blind, Active Controlled, Parallel Group, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar in Combination with Metformin Compared to Glimpiride in Combination with Metformin in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Therapy Alone.  CV-168-048.  Bristol-Myers Squibb.  Author and Principal Investigator.  8/04-present.

 

BIPI Protocol 502.421. A randomized, double-blind, double-dummy, placebo-controlled, forced-titration, comparison of MICARDIS HCT (telmisartan 80 mg/Hydrochlorothiazide 25) versus DIOVAN HCT (valsartan 160 mg/hydrochlorothiazide 24 mg) using seated trough cuss blood pressure in patients with stage 1 and stage 2 hypertension – IND #42450  Boehringer Ingelheim.  Author and Principal Investigator, 8/03 – 9/04.

 

Rosiglitazone in combination with glimpiride compared to glimperide plus placebo for 24 weeks in subjects with Type 2 diabetes mellitus how are inadequately controlled on noe-TZD oral therapy.  GlaxoSmithKline.  Author and Principal Investigator.  3/03- 12/03.

 

Clinical utility of Amlodipine/Atorvastatin to improve concomitant cardiovascular risk factors of hypertension and Dyslipidemia.  Pfizer.  Author and Principal Investigator. 7/02 – 12/03.

 

Dose finding efficacy and safety of AZ 242 in subjects with Type 2 Diabetes.  Astra Zeneca.  Author  and Principal Investigator.  7/02 – 8/03.

 

A 48 week open label non-comparative, phase III B study to evaluate the efficacy and safety of the lipid regulation of AZ 4522/ 91.  Astra Zeneca.  6/02 – -12/04.

 

Phase II B, multi-center, double-blind, randomized, placebo and active controlled, parallel group, dose-finding study to evaluate the efficacy and safety of once daily oral administration of placebo, 5 mg, 10 mg, 25 mg, and 50 mg of MI 00240/2004 or lisinopril for 8 weeks in subjects with mild to moderate hypertension.  Biovail.  Author and Principal Investigator.  3/01 – 3/02.

 

A Double Blind, Randomized, Parallel Group, Dose Response, Multi-Center, Study to Compare the Safety and Efficacy of Diltiazem HCL Extended Release Capsules (G99) to Placebo Dosed at Bedtime to G99 Dosed in the Morning in Patients with Essential Hypertension. Biovail. Author and Principal Investigator. $85,000. 6/00 – 5/01.

 

Trial to Assess the Long Term Safety and Efficacy of ZD4522 in Subjects in the ZD4522 Clinical Trial Program.  Astra-Zeneca.  $4,198.50.  Author and Principal Investigator.  6/00 – 12/04.

 

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel 9-week study of BMS-189921 in the Treatment of Mild to Moderate Hypertension.  Bristol-Myers Squibb.  $35,100.00.  Author and Principal Investigator.  2/00 – 7/00.

 

“A 24-week Randomized Multicenter Trial to Evaluate the Efficacy and Safety of ZD4522 and Niaspan, Alone and in Combination, in the Treatment of Subjects with Type II b and IV Hyperlipidemia”.  Astra Zeneca.  $31,682.00.  Author and Principal Investigator.  .

 

“A Randomized, Double-Blind, Amlodipine-and-Losartan-Controlled Study of Omapatrilat in Subjects with mild to moderate Hypertension”.  Bristol Myers-Squibb.  $29,855.00.  Author and Principal Investigator.  3/99 – 6/00.

 

“Elective Titration Study of Omapatrilat in The Treatment of Mild-to-Moderate Hypertension.”  Bristol-Myers Squibb.  $37,112.00.  Author and Principal Investigator.  6/98 – 9/00.

 

“An Open-Label, Community Based Clinical Practice Study of Niaspan in Patients with Hyperlipidemia.”  KOS Pharmaceuticals.  $3,900.00.  Author and Principal Investigator.  8/99 – 6/00.

 

“A Multicenter, Randomized, Double-Blind, Amlodipine-and Placebo-Controlled, 10-Week Study of Omapatrilat in the Treatment of Mild to Moderate Hypertension."  Bristol-Myers Squibb. $41,640.00.  Author and Principal Investigator. .4/98 – 2/00.

 

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 9-Week Dose-Ranging Study of Omapatrilat in the Treatment of Mild to Moderate Hypertension."  Bristol-Myers Squibb.  $54,600.00. Author and Principal Investigator.  12/97 – 12/98.

 

“Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel, 2 Week Dose-Finding Study of the Dual Metalloprotease Inhibitor, BMS-189921, in the Treatment of Mild to Moderate Hypertension:  A Pilot Study."  Bristol-Myers Squibb.  $45,444.00.  Author and Principal Investigator.  7/97 – 12/97.

 

"A Study of the Dual Metalloprotease Inhibitor, BMS-186716, in the Treatment of Mild to Moderate Hypertension."  Bristol-Myers Squibb.  $65,535.00 Author and Principal Investigator.  7/96 – 7/97.

 

"A Multicenter, Randomized, Double-Blind Trial of the Anti-hypertensive Efficacy and Safety of Irbesartan compared to Losartan in the Treatment of Mild to Moderate

Hypertension."  Bristol-Myers Squibb.  $19,600.00  Author and Principal Investigator.  1/97 – 12/97.

 

"Open-Label, Long-Term Study of the Anti-Hypertensive Activity and Safety of BMS-186716, A Dual Metalloprotease Inhibitor, in the Treatment of Hypertension.  Bristol-Myers Squibb.  $218,698.69.  Author and Principal Investigator.  11/96 – present.

 

"A Multicenter, Randomized Double-Blind, Placebo and Active-Controlled, Parallel 12 Week Dose-Ranging Study of the Dual Metalloprotease Inhibitor, BMS-186716, in the Treatment of Mild to Moderate Hypertension.  Bristol-Myers Squibb.  $41,400.00. Author and Principal Investigator

 

"A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Parallel 8 week dose-Ranging Study of the dual Metalloprotease Inhibitor, BMS-186716 in the Treatment of Mild to Moderate Hypertension."  Bristol-Myers Squibb.  $48,300.00. Author and Principal Investigator

 

"Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two Week Dose-Finding Study of the Dual Metalloprotease Inhibitor, BMS-18676, in the Treatment of Mild to Moderate Hypertension:  A Pilot Study."  Bristol-Myers Squibb.  $26,485.20.  Author and Principal Investigator

 

"The Efficacy and Safety of SR47436 (BMS186295) Added to Hydrochlorothiazide for the Treatment of Hypertension in Subjects Nonresponsive to Hydrochlorothiazide Alone."  Bristol-Myers Squibb.  $5,000.00.  Author and Principal Investigator

 

"Factorial Trial of the Efficacy and Safety of Multiple Doses of SR47436/BMS186295 and HCTZ in Mild to Moderate Hypertension."  Bristol-Myers Squibb.  $80,770.00.  Author and Principal Investigator

 

"Multicenter Randomized Double-Blind Placebo-Controlled Trial of SR47436/BMS186295 for Treatment of Hypertension."  Bristol-Myers Squibb.  $60,540.00.  Author and Principal Investigator

"Dose Ranging Study II:  A Multicenter Trial of the Anti-Hypertensive Activity and Safety of 100, 200, and 300 mg SR47436 (BU5-186295) in Mild to Moderate Hypertension.  Bristol-Myers Squibb.  $94,213.50Author and Principal Investigator

 

"A Multicenter Eight-Week Study of the Anti-Hypertensive Activity and Safety of BMS-186295/SR 37336 in Mild to Moderate Hypertension. Bristol-Myers Squibb. $164,520.00.  Author and Principal Investigator

 

 “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Trial of ANA-756 in Patients with Essential Hypertension." Wyeth-Ayerst.  $11,516.80.  Author and Principal Investigator. 3/11/94 - 11/20/94.

 

"A Dose Response, Placebo-Controlled Trial of BMS 180431 for Primary Hypercholesterolemia;" Bristol-Myers Squibb.  $32,208.00.  Author and Principal Investigator.

 

"Fosfomycin Tromethamine versus Nitrofurantoin Monohydrate/Macrocrystals in Uncomplicated Urinary Tract Infections," Forest Laboratories.  $35,000.00 Author and Principal Investigator.

 

"A Study to Compare the Relative Efficacy and Safety of Toprol 50 mg XL versus Lopressor 100 mg Administered Once Daily to Patients with Mild to Moderates Hypertension," Astra Pharmaceuticals.  $53,472.00.  Author and Principal Investigator, 11/1/92 - 6/30/94.

 

"Fostomycin Tromethamine vs Ciprofloxacin in Uncomplicated Lower Urinary Tract Infections," Forest Laboratories.  $36,000.00.  Author and Principal Investigator.  6/1/91 - 6/30/94.

 

"Efficacy and Safety of Pravastatin in Patients with Primary Hypercholesterolemia Compared with Placebo," Bristol-Myers Squibb.  $8,450.00  Author and Principal Investigator.  8/1/92 - 6/30/94.

 

"Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Trandolapril Alone and in Combination with Verapamil (Isoptin-SR)," Knoll Pharmaceuticals.  $52,000.00.  Author and Principal Investigator.  9/1/92 - 6/40/94.

 

"Efficacy and Tolerability of Simvastatin in the Treatment of Primary Hypercholesterolemia," Merck and Company.  $7,000.00.  Author and Principal Investigator.  8/1/92 - 6/30/94.

 

"A Comparison of the Combination of Fosinopril 10 mg with Hydrochlorothiazide 12.5 mg with Placebo in Patients with Mild to Moderate Hypertension Utilizing Ambulatory Monitoring," Bristol-Myers Squibb.  $32,000.00.  Author and Principal Investigator. 12/1/91 - 7/31/92.

 

"Efficacy and Tolerability of Extended Release Felodipine in Adult Patients with Mild to Moderate Uncomplicated Essential Hypertension," Merck.  $7,000.00.  Author and Principal Investigator. 12/1/91 - 8/30/92

 

"A Comparison of the Combination of Fosinopril 20 mg with Hydrochlorothiazide 12.5 with Placebo in Patients with Mild to Moderate Hypertension Utilizing Ambulatory Monitoring."  Bristol-Myers Squibb.  $42,000.00.  Author and Principal Investigator. 1/15/91 - 8/30/92.

 

"Evaluation of the Urine Dipstick in Screening of Asymptomatic Patients."  Ames Division of Miles Laboratories.  $45,136.00.  Author and Principal Investigator. 2/1/91-6/30/92.

 

"A Double-Blind, Placebo-Controlled, Ascending Multiple Oral Dose Clinical Study of CS-622 to Assess the Duration of Action in Patients with Mild to Moderate Essential Hypertension:  Once Daily (Q.D.) vs Twice Daily (B.I.D.) Regimens."  Sankyo, U.S.A.  $37,500.00.  Author and Principal Investigator. 2/1/91-6/30/92.

 

"A Multicenter Trial to Evaluate Efficacy and Lipid Effects of Doxazosin vs Initial Therapy in Mild to Moderate Essential Hypertension."  Pfizer, Inc.  $8,000.00.  Author and Principal Investigator. 10/1/90-6/30/91

 

"Double-Blind, Randomized Trial of the Safety and Efficacy of Captopril Compared to Placebo in the Treatment of Isolated Systolic Hypertension."  Bristol Myers-Squibb.  $19,995.00. Author and Principal Investigator. 1/1/91-6/30/93.

 

"Zofenopril in the Management of Mild to Moderate Hypertension," Squibb Institute for Medical Research.  $20,000.00 Author and Principal Investigator.  10/1/89-6/30/90.

 

"Diltiazem-SR in Mild to Moderate Hypertension," Bolar Pharmaceuticals.  $25,000.00.  Author and Principal Investigator. 10/1/89-present.

 

"Clarithromycin in the Management of Community Acquired Pneumonia in Ambulatory Patients," Abbott Laboratories.  $2,000.00.  Author and Principal Investigator. 10/1/89-6/30/90.

 

"A Long-Term, Multicenter, Glycemic Control Study in Outpatients With Non-Insulin Dependent (Type-II) Diabetes," Bolar Pharmaceutical Company.  $70,200.00. Author and Principal Investigator. 7/1/89-6/30/91.

 

"Temafloxacin versus Trimethoprim/Sulphamethoxazole in Uncomplicated Urinary Tract Infection," Abbott Laboratories.  $14,400.00. Author and Principal Investigator. 2/1/89-5/30/89.

 

"Isoptin in the Treatment of Mild to Moderate Hypertension," Knoll Pharmaceuticals.  $22,000.00.  Author and Principal Investigator. 3/1/88-9/30/88.

 

"Voltaren in the Treatment of Osteoarthritis," Ciba-Geigy.  $12,000.00. Author and Principal Investigator. 7/1/87-12/31/87.

 

"Protocol to Determine the Effect of SQ 29,852 on Blood Pressure in Patients with Mild to Moderate Essential Hypertension," Squibb Institute for Medical Research.  $57,875.00.  Author and Principal Investigator. 9/1/87-6/30/89.

 

"The Determination of the Incidence of Legionella Infection in Ambulatory Lower Respiratory Tract Infections," Family Health Foundation of America.  $14,499.00.  Author and Principal Investigator. 11/1/85-10/31/86.

 

"Etiologic Evaluation of Pharyngitis and its Clinical Response to Antibiotic Therapy," Abbott Laboratories.  $32,000.00.  Author and Principal Investigator. 9/1/85-2/28/86.

 

Placebo-Controlled Trial of Fosinopril Sodium Added to Chlorthalidone 25 mg Daily for

the Treatment of Mild to Moderate Hypertension," Squibb Institute for Medical Research.  $45,000.00.  Author and Principal Investigator. 9/1/86-12/31/87.

 

"Capoten in the Treatment of Congestive Heart Failure," Squibb Institute for Medical Research.  $3,000.00. Author and Principal Investigator. 5/1/86-12/31/86.

 

"The Determination of Urine Specific Gravity," Ames Division, Miles Laboratories.  $10,000.00.  Principal Investigator.

 

GRANTS - Co-Investigator

 

Since July of 1983, I have assisted Dr. Glenn Apseloff and Dr. Nicholas Gerber in the Research Program in Clinical Pharmacology.  I currently serve as Associate Director of Clinical Pharmacology.  In this role, I review the Phase I research protocols, I provide physician coverage to evaluate the patients, and I provide physician coverage for any patient problems that may occur during or after the protocols.

 

Since July 1, 1983, I have served as Co-Investigator on about 145 projects.

 

UNIVERSITY SERVICE

            7/2001 – 6/2004.  Member, Research Committee of the Ohio State University

 

HOSPITAL SERVICE

 

Member, OSU Hospitals Pharmacy and Therapeutics Committee, and Chairman of Formulatory Subcommittee, 1992-1999.

 

Chairman, Ambulatory Quality Assurance Committee, Ohio State University Hospitals, July 1, 1985-June 30, 1989

Responsibilities:

§         Developed and implemented a quality assurance program in the University Hospitals Clinic

§         Joint Commission on Accreditation of Hospitals regulations.

Member, Medical Education Committee, Saint Anthony Medical Center, January 1, 1983-1990

 

COMMUNITY SERVICE

 

President, Riverside Civic Association, Northwest Columbus, January 1, 1985-December 31, 1985.

 

From April, 1985 through December 1998, I was once or twice a month guest on the WOSU (AM 820) radio show "Open Line."  I answered general medical questions from the radio audience throughout a one to one and one-half hour show.  The show was hosted by Tom Wiebell.

 

Consultant to the State of Ohio Medical Board, Pharmacy Board, and Attorney General.  This work involves serving as an expert witness in cases brought by the State of Ohio for alleged over-prescribing of controlled substances.  I have also served as an expert witness in several criminal prosecutions.

 

From October, 1992 through December 1998, I was a co-host of "Body Talk," a nationally syndicated radio call in show.  The show was broadcast on 45 stations in the U.S. and in over 120 countries internationally on the Armed Forces Radio Network.  Listeners could call in and ask general health questions.  The show ran for one hour, and I was one of six physicians who rotated on the show on an every six-week rotation. 

 

From December 1998 through the present, I serve as a regular guest, once a month for one hour on WOSU Radio “Open Line”, hosted by Fred Aarderle.  I discuss medical issues with the host and various callers. 

 

October 1998 to March 2000 Member Board of Trustees, United Methodist Children’s Home, Worthington, Ohio.